Immunovant (IMVT) Other Non Operating Income (2018 - 2026)

Immunovant (IMVT) has 9 years of Other Non Operating Income data on file, last reported at $798000.0 in Q1 2026.

• Quarterly Other Non Operating Income fell 25.49% year-over-year to $798000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 364.04% YoY) and the FY2026 annual result came in at $2.2 million, up 363.06% from the prior year.
• Other Non Operating Income grew to $798000.0 in Q1 2026, from -$54000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $1.2 million in Q2 2025 to a low of -$2.6 million in Q1 2024.
• A 5-year average of $84235.3 and a median of $354000.0 in 2022 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2022 — Other Non Operating Income plunged 1441.23% — and 2025, when it soared 4139.29%.
• Tracing IMVT's Other Non Operating Income over 5 years: stood at -$1.8 million in 2022, then jumped by 162.27% to $1.1 million in 2023, then slumped by 214.99% to -$1.3 million in 2024, then jumped by 95.71% to -$54000.0 in 2025, then jumped by 1577.78% to $798000.0 in 2026.
• The last three Other Non Operating Income figures came in at $798000.0 (Q1 2026), -$54000.0 (Q4 2025), and $250000.0 (Q3 2025), per Business Quant data.